Heart HealthPCSK9 Inhibitor Prevents Heart Disease in Diabetics Without Known Atherosclerosis
A groundbreaking trial found that evolocumab, a PCSK9 inhibitor, reduced major cardiovascular events by 22% in diabetic patients without known significant atherosclerosis. The VESALIUS-CV trial followed over 9,000 participants for nearly 3 years, demonstrating that aggressive cholesterol lowering can prevent heart attacks and strokes even in patients without established heart disease. This represents a paradigm shift toward earlier intervention in diabetes management, potentially extending healthspan by preventing cardiovascular complications that typically shorten lifespan in diabetic individuals.
